# US 2014/0120133 A1 · Vaccine Against African Horse Sickness Virus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0120133 A1 - Document ID: US20140120133A1 - Status: Published application - Kind: A1 - Application number: 14/060,023 - Filed: 2013-10-22 - Published: 2014-05-01 - Earliest claimed: 2012-01-25 - Assignees: Merial Limited; University of Pretoria; The Regents of the University of California - Inventors: Jules Maarten Minke; Jean Christophe Audonnet; Alan John Guthrie; Nigel James Maclachlan; Jiansheng Yao - Web page: https://patentgrep.com/patent/US20140120133A1 ## CPC - A61K 39/15: Reoviridae, e.g. calf diarrhea virus - A61K 39/12: Viral antigens - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - A61P 37/04: Immunostimulants - C07K 14/005: from viruses - C12N 15/86: Viral vectors - A61K 2039/53: {DNA (RNA) vaccination} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/552: {Veterinary vaccine} - A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers} - A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59} - C12N 2710/24043: viral genome or elements thereof as genetic vector - C12N 2720/12122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2720/12134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions. ## Claims ### Claim at position 1 1-43. (canceled) ### Claim 44 A vaccine composition comprising a recombinant poxvirus wherein the recombinant poxvirus comprises a nucleic acid molecule encoding an African Horse Sickness Virus (AHSV) VP2 polypeptide; and wherein the composition is capable of eliciting a protective immune response in an equine animal. ### Claim 45 (depends on 44) The composition of claim 44, wherein the nucleic acid encodes a polypeptide having an amino acid sequence as set forth in SEQ ID NO:1, 30, 44, 49, or 50-63. ### Claim 46 (depends on 45) The composition of claim 45, wherein the nucleic acid has the sequence as set forth in SEQ ID NO:4, 18, 28, 42 or 48. ### Claim 47 (depends on 46) The composition of claim 46 wherein the nucleic acid has the sequence as set forth in SEQ ID NO:18 or 28. ### Claim 48 (depends on 44, 45, 46, 47) The composition of any one of claims 44 to 47 further comprising a carboxypolymethylene adjuvant. ### Claim 49 (depends on 48) The composition of claim 48 wherein the adjuvant is CARBOPOL® 974P. ### Claim 50 (depends on 49) The composition of claim 49 wherein the adjuvant is present in an amount of about 4 mg/mL. ### Claim 51 An expression vector comprising a polynucleotide having the sequence as set forth in SEQ ID NO:4, 28, 42 or 48; wherein the vector is capable of eliciting a protective immune response in an equine animal against AHSV. ### Claim 52 (depends on 51) The vector of claim 51 wherein the nucleic acid has the sequence as set forth in SEQ ID NO:28. ### Claim 53 (depends on 52) The vector of claim 52, wherein the vector is a canarypox or a fowlpox vector. ### Claim 54 (depends on 53) The vector of claim 53, wherein the polynucleotide is operably linked to a promoter selected from the group consisting of H6 vaccinia promoter, I3L vaccinia promoter, 42K poxyiral promoter, 7.5K vaccinia promoter, and Pi vaccinia promoter. ### Claim 55 (depends on 51, 52, 53, 54) An isolated host cell transformed with the vector of any one of claims 51 to 54. ### Claim 56 (depends on 48) A method for inducing a protective immunological response in an animal comprising administering to the animal an effective amount of the composition of claim 48. ### Claim 57 (depends on 48) A method of vaccinating an animal susceptible to African Horse Sickness comprising administering at least one dose of the composition of claim 48. ### Claim 58 An isolated African Horse Sickness Virus AHSV4-Jane strain, having a nucleic acid sequence comprising the sequence as set forth in SEQ ID NO:48. ### Claim 59 An isolated polypeptide having the sequence as set forth in SEQ ID NO: 1, 30, 44 or 49. ### Claim 60 An isolated nucleic acid having the sequence as set forth in SEQ ID NO: 4, 18, 28, 42 or 48. ### Claim 61 (depends on 60) The nucleic acid of claim 60 having the sequence as set forth in SEQ ID NO:28.